DxS and BTG to Market AstraZeneca s DNA Diagnostic Technology | GenomeWeb

NEW YORK, March 23 (GenomeWeb News) - DxS and BTG said today that they have signed an exclusive license to commercialize technology developed by AstraZeneca for the detection of SNPs and other gene mutations.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.